ArticleInternational journal of general medicine2026
Analysis of Platelet Membrane Glycoproteins and The Specific Antibodies in MYH9-Related Diseases.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To comparatively analyze platelet membrane glycoprotein expression profiles and antiplatelet-specific antibody levels in patients with MYH9-related disorders (MYH9-RD) versus immune thrombocytopenia (ITP), and to evaluate their potential clinical significance. Methods: From July 2017 to June 2025, a total of 20 patients with MYH9-RD, 20 patients with ITP, and 20 healthy controls were enrolled. Platelet membrane glycoprotein expression of CD41 (GPIIb), CD42a (GPIX), CD42b (GPIb), CD61 (GPIIIa), and CD62P (GMP140), platelet-leukocyte aggregation ratios, and antiplatelet-specific antibody levels were analyzed using flow cytometry. Inter-group differences in platelet membrane glycoprotein expression were compared using the Kruskal-Wallis test. Results: The MYH9-RD cohort demonstrated significantly higher median fluorescence intensity of platelet membrane glycoproteins (CD41, CD42a, CD42b, CD61, and CD62P) compared to ITP and healthy control groups ( Conclusion: Significant differences in platelet membrane glycoprotein expression profiles and antiplatelet-specific antibody levels distinguish MYH9-related disorders (MYH9-RD) from immune thrombocytopenia (ITP). These findings have important clinical implications, providing potential biomarkers for the differential diagnosis of MYH9-RD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.